Multiple sclerosis: side effects of interferon beta therapy and their management
about
Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic reviewReview of interferon beta-1b in the treatment of early and relapsing multiple sclerosisRisk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple SclerosisPharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.Issues and practices in multiple sclerosis.The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study.Interferon-beta1a for the treatment of multiple sclerosis.Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon β.Lymphocyte subtypes in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarateOptimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.Disease-modifying agents in multiple sclerosis.Treatment discontinuation in multiple sclerosis: The French Web-based survey ALLIANCE3,3'-diindolylmethane ameliorates experimental autoimmune encephalomyelitis by promoting cell cycle arrest and apoptosis in activated T cells through microRNA signaling pathways.Beta-interferons in multiple sclerosis: a single center experience in India.Multiple Sclerosis State of the Art (SMART): A Qualitative and Quantitative Analysis of Therapy's Adherence, Hospital Reliability's Perception, and Services Provided QualityThe safety and efficacy of IFN-beta products for the treatment of multiple sclerosis.Interferon therapy for acute hepatitis C during pregnancy.Is this septic shock? A rare case of distributive shock.Multiple cutaneous necrotic lesions associated with Interferon beta-1b injection for multiple sclerosis treatment: A case report and literature reviewEffect of drugs in secondary disease progression in patients with multiple sclerosis.Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple SclerosisThrombotic microangiopathy associated with use of interferon-betaSpasticity in multiple sclerosis and role of glatiramer acetate treatment.The conundrum of iron in multiple sclerosis--time for an individualised approach.Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala studyThe importance of maintaining effective therapy in multiple sclerosis.Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management.Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.Early stage and long term treatment of multiple sclerosis with interferon-betaDevelopment of autoimmune hepatitis type 1 after pulsed methylprednisolone therapy for multiple sclerosis: a case report.Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab.Why health expectations and hopes are different: the development of a conceptual model.Current disease-modifying treatment of multiple sclerosis.Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.Multiple sclerosis and pain.Orofacial adverse effects of biological agents.Side effects of cytokines approved for therapy.Hughes syndrome and multiple sclerosis.Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs.
P2860
Q22241795-0702CC7D-D39F-45B5-A925-2AD8B026468EQ24652353-9E3550F6-82D7-4539-BF03-739654938D5DQ28087414-7284420D-0B1E-46B7-A93A-F1B78DDA9D02Q30379738-C1004A24-102C-4912-BACC-29849F101DB8Q30751454-62DBEB4F-C6D5-49CD-9C63-C123EF174FE3Q30997352-5BD2E8A8-F402-4BD6-B67B-229A1A5A9FADQ31106233-253D509C-1CD1-4728-8CC9-FE136974E58FQ33413368-EACF3AA7-F2F0-46F0-86E8-5657F0B9487FQ33613102-6B630431-2013-4658-B8A6-93FA9AA8C2DAQ33644812-C3BB06E9-3A59-46BB-AA46-F2FB7657D2D6Q33670940-A81D0F28-8A44-4E1B-92ED-78C1C64D0E1AQ33692801-51D024ED-B72B-4764-8F40-C7F83D5A8DD0Q33944014-B4BF1B0A-0041-45AB-9250-5BD10A05E473Q34075859-D6D3197A-C731-41C6-A113-CB0E30D4F2ABQ34152800-0587EB42-60B3-453A-98F4-ABD16C4AD74EQ34579232-AF17136B-DDA9-499E-A79B-2D76063FDC73Q34979661-DD61586D-4F00-473E-BB28-915FC63A0105Q35006044-1DDE50C7-4887-402D-87A3-E644D6A16D1EQ35564621-9D296F01-DCA4-46D5-83D1-B8EC3715065DQ35818152-F0E4740A-FDCA-4E19-887D-E87573B02176Q35902459-329F6ECB-509D-4D91-92A4-F8F0EA46B537Q36101957-3DB17143-9B64-4611-B0B9-EEF83EA7BD15Q36109866-56C7CAB3-E129-4B0F-B408-DD91CAE613FBQ36110218-2E3D4C71-6371-4C89-BC4A-8D22762DA797Q36171531-F54DA3A4-2323-461A-B641-0095AB425334Q36260724-D4CDFAB6-737D-45B3-B2AC-0E5589C81985Q36419566-DC1B8B80-3686-498F-9488-F81E3BA94DE2Q36775237-3ACE1746-6D2A-414C-B56F-E91F3958218DQ37001036-AFAB4849-42E7-4165-94A9-2FDA78E8EA4EQ37303237-1B1231E2-7180-4813-9428-3A6A7D4241D1Q37347316-EE708C50-2795-47C3-B8C1-ACD9AB40487BQ37389500-48C9486E-97AB-4B48-8252-C04AF1FBB65AQ37581949-BEF544B4-70D9-43FD-AFB6-C3F28C30C196Q37855719-81580965-C298-434C-A12D-23337D9CC79AQ38004932-0CDBB4D8-93FB-40F2-B2D9-6626BED100DBQ38036427-A78F8577-08E4-44E3-8D71-EBE242D6F280Q38213692-0BC2E153-94B1-4187-9D71-E6B75065C8FCQ38255698-84D1321A-E229-4C19-9F70-0C8264FA264EQ38261156-77D43EC5-BB33-4147-9824-45B245E4F77AQ38315992-D435841D-D616-4524-8AF0-52FFAA94A254
P2860
Multiple sclerosis: side effects of interferon beta therapy and their management
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Multiple sclerosis: side effects of interferon beta therapy and their management
@ast
Multiple sclerosis: side effects of interferon beta therapy and their management
@en
Multiple sclerosis: side effects of interferon beta therapy and their management
@nl
type
label
Multiple sclerosis: side effects of interferon beta therapy and their management
@ast
Multiple sclerosis: side effects of interferon beta therapy and their management
@en
Multiple sclerosis: side effects of interferon beta therapy and their management
@nl
prefLabel
Multiple sclerosis: side effects of interferon beta therapy and their management
@ast
Multiple sclerosis: side effects of interferon beta therapy and their management
@en
Multiple sclerosis: side effects of interferon beta therapy and their management
@nl
P356
P1433
P1476
Multiple sclerosis: side effects of interferon beta therapy and their management
@en
P2093
E U Walther
R Hohlfeld
P304
P356
10.1212/WNL.53.8.1622
P407
P577
1999-11-10T00:00:00Z